Gerri Henwood has served as our President, Chief Executive Officer and a director of the Company since November of 2019. From 2008 to December 2020, Ms. Henwood was the President, Chief Executive Officer and a director of Recro Pharma, Inc. (REPH), a company she founded in 2008. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Before founding MCG, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc. (formerly AUXL), or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., or IBAH, a contract research organization listed on NASDAQ. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director—Marketing in the International Pharmaceutical Division.

Ms. Henwood previously served on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from 2015 until its acquisition by La Jolla Pharmaceutical Company in June 2020. Before that, she served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceuticals company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood also served on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc.

Ms. Henwood holds a B.S. in Biology from Neumann University.

Diane Myers serves as the Senior Vice President, Regulatory and Quality. Before her role at Baudax Bio, she served as the Senior Vice President, Regulatory and Quality at Recro Pharma from 2008 to November 2019. From 2008 to 2014, Ms. Myers also served as Senior Vice President of Regulatory Affairs and Quality Assurance for MCG, a pharmaceutical incubator and consulting firm. From 2000 to 2008, Ms. Myers served as Vice President of Regulatory Affairs and Quality at Auxilium. In addition, for more than 15 years she held positions of increasing responsibility at GlaxoSmithKline plc in the Quality Control and Quality Assurance groups within the Biopharmaceutical Research and Development Division.

Ms. Myers holds a B.S. in Biology from Neumann University.

Ms. McAndrew, age 49, is a Director with Danforth, an advisory firm focused on providing financial strategy to life science organizations, and has been employed with Danforth since August 2021. Prior to Danforth, Ms. McAndrew was the VP, Corporate Controller of Tmunity Therapeutics, Inc., a biotechnology company, from January 2021 to July 2021. Ms. McAndrew previously served as Head of Accounting Operations at Spark Therapeutics, Inc., a biotechnology company, from March 2015 until January 2021. Prior to this, Ms. McAndrew served as Corporate Controller for over 8 years in other privately held and public companies at various life cycle stages, managing finance, accounting, and other corporate operational functions. Ms. McAndrew is a certified public accountant and holds a B.S. degree in Accounting from King’s College.